Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Bromodomain and extra-terminal domain (BET) proteins and spleen tyrosine kinase (SYK) are key targets in diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma (BL).
• Investigating novel therapeutic combinations is crucial for improving treatment outcomes in these B-cell malignancies.

Purpose of the Study:

• To evaluate the in vitro anti-lymphoma activity of BET inhibitors (AZD5153 and I-BET151) alone and in combination with the SYK inhibitor Entospletinib.
• To elucidate the molecular mechanisms underlying the combined inhibition of BET and SYK pathways in DLBCL and BL cell lines.

Main Methods:

• Assessed the effects of single-agent and combination treatments on cell proliferation, metabolic activity, apoptosis, and cell cycle progression in DLBCL and BL cell lines.
• Utilized RNA sequencing (RNAseq) to analyze gene expression changes in SU-DHL-4 cells following combined AZD5153 and Entospletinib treatment.
• Performed functional enrichment analyses to identify key biological pathways and potential regulatory genes modulated by the combination therapy.

Main Results:

• Both BET inhibitors demonstrated dose- and time-dependent reductions in lymphoma cell proliferation and metabolic activity.
• Combination therapy of BET and SYK inhibitors synergistically enhanced anti-proliferative effects and induced a G0/G1 cell cycle arrest.
• Combined treatment led to significant gene expression modulation, with specific enrichment in DNA replication and cell division pathways, identifying potential key regulators.

Conclusions:

• Simultaneous inhibition of BET and SYK pathways represents a promising therapeutic strategy for DLBCL and BL.
• The combination therapy induces a unique gene expression signature associated with cell cycle regulation, supporting its anti-lymphoma efficacy.